Received Mar 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | M2RH3 | — |
patient was given the pediatric dose; patient was given the pediatric dose; This non-serious case was reported by a other health professional via patient support programs and described the occurrence of underdose in a 45-year-old female patient who received HBV (Engerix B pediatric) (batch number M2RH3, expiry date 21-FEB-2026) for prophylaxis. On 24-FEB-2025, the patient received Engerix B pediatric. On 24-FEB-2025, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: patient was given the pediatric dose) and adult use of a child product (Verbatim: patient was given the pediatric dose). The outcome of the underdose and adult use of a child product were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-FEB-2025 The other health professional reported that 45 year old patient was given the pediatric dose which led to underdose and adult use of a child product.